Hamburg SME specializing in clinical outcomes measurement and data analytics for large-scale stroke and neurological intervention trials.
EPPDATA GmbH is a Hamburg-based health data and clinical outcomes company that provides data management, patient reported outcome measurement (PROM), and value-based healthcare analytics to large clinical trials. In the stroke research space, they have contributed to randomized controlled trials evaluating both neuroprotective therapies and endovascular interventions, suggesting expertise in designing and operating the data capture and outcomes measurement infrastructure that such trials require. Their participation in multi-country stroke trials points to capabilities in handling complex, multi-site clinical datasets and translating them into health economics-relevant endpoints. As a small private company embedded in major EU-funded trial consortia, their practical value lies in bridging clinical trial execution with outcomes research and health system value assessment.
TENSION (2018-2023) explicitly lists 'patient reported outcome measurement' and 'value-based healthcare' among its core keywords, indicating EPPDATA's likely contribution to outcomes methodology in that trial.
EPPDATA participated in both PROOF and TENSION, both large randomized controlled trials in acute stroke requiring systematic data collection across multiple clinical sites.
PROOF (2017-2023) focused on normobaric oxygen as a neuroprotective agent and used biomarkers to measure effect, areas where EPPDATA contributed as a trial partner.
The TENSION project's keyword set includes 'value-based healthcare', suggesting EPPDATA is developing capabilities in health economics evaluation alongside clinical outcomes work.
In their earliest H2020 project (PROOF, 2017), EPPDATA's focus was on the biological side of stroke intervention — neuroprotection mechanisms, oxygen therapy, and biomarker measurement. By their second project (TENSION, 2018), the emphasis had clearly shifted toward the clinical and economic dimensions of stroke care: thrombectomy procedures, functional outcomes, patient-reported outcomes, and value-based healthcare frameworks. This suggests a deliberate move from supporting lab-oriented trial endpoints toward building expertise in outcomes research and health system value demonstration — a transition that reflects broader industry demand for real-world evidence and cost-effectiveness data. The trajectory points toward a company repositioning itself as a specialist in health outcomes measurement rather than a generalist clinical trial data house.
EPPDATA appears to be moving toward health economics and patient-centered outcomes measurement, making them a useful partner for trials or consortia that need to demonstrate real-world clinical value and cost-effectiveness to payers or health technology assessment bodies.
EPPDATA has participated exclusively as a non-leading partner in both of its H2020 projects, indicating a specialist contributor model rather than a consortium-building role. Despite only two projects, they have engaged with 27 unique partners across 15 countries, which suggests that each project they join is a large, ambitious multi-center trial rather than a small bilateral collaboration. This profile — high partner diversity, no coordination role, deep sectoral focus — is characteristic of a niche data or methodology firm that gets invited into large clinical consortia for a specific technical function.
EPPDATA has built a remarkably broad network for a two-project SME, with 27 unique partners spanning 15 countries — an average of over 13 partner organizations per project. This indicates consistent participation in large, pan-European clinical trial consortia, likely including university hospitals, neurology departments, and health technology assessment bodies across multiple EU member states.
EPPDATA occupies a narrow but defensible niche: a private SME with documented experience in both the biological and outcomes measurement dimensions of acute stroke trials, bridging neuroprotection science and value-based healthcare — a combination that is genuinely rare among small companies. For consortium builders in stroke, neurology, or brain health, they offer the dual credibility of having contributed to both a mechanistic oxygen therapy trial (PROOF) and a landmark thrombectomy RCT (TENSION), two very different methodological contexts. Their small size and Hamburg base make them a flexible, cost-efficient partner for outcomes and PROM methodology work in health-focused EU projects.
